Advertisement


Hannah Choe, MD, on Dynamics of Overall and Organ-Specific Responses to Axatilimab in Chronic Graft-Versus-Host Disease: Analysis from the AGAVE-201 Study

2024 ASH Annual Meeting

Advertisement

Hannah Choe, MD, of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital, reviews results from a secondary analysis of the phase 2 AGAVE-201 study, which assessed axatilimab, an anti-colony stimulating factor 1 receptor monoclonal antibody, in the setting of chronic graft-versus-host disease (cGVHD). Dr. Choe reports on findings from the secondary analysis, which assessed the timing/dynamics of clinical and symptom responses in patients with cGVHD with axatilimab in AGAVE-201 (Abstract 98).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Agave 2.01 was an open label multicenter, randomized study of axatilimab at three different doses. This study met its primary endpoint with an NIH clinical response rate of 73% within the first six treatment cycles. It also met its key secondary endpoint with a seven point or more improvement in the modified Lee symptom scale of 55.1% of patients. In this analysis that we presented in the abstract at ASH 2024, we looked at those responders with NIH clinical response or mLSS symptom response. We evaluate the dynamics of these responses overall and by organ and also between the NIH clinical and symptoms scores. Responsive patients reflected the overall study population. There was heavy pre-treatment and also majority of patients with severe disease. The fastest responding organs by clinical responses were the upper GI tract, lower GI tract, joints, fascia, esophagus, and liver. With median responses seen 1.0 to 1.9 months. More than half of these responses were seen by day 56, if not day 84. The more fibrotic manifestations, which included the mouth, lungs, eyes, and skin, took longer to respond with median 2.1 to 3.2 months. But interestingly, we found that patients had symptom improvements as seen by improvements in their mLSS symptom scales faster with their NIH clinical responses in these slower responsive organs, including the mouth, lungs, and eyes, and trended towards significance with the skin. These responses were seen in the first one to two months. We now understand better how and when patients respond to axatilimab as assessed by clinicians with the NIH clinical response and patients from the patient reported outcomes from the modified Lee symptom scale. Importantly, patients responded with symptom improvements preceding that of the clinician, and this was seen particularly with the fibrotic manifestations, axatilimab, thus demonstrated rapid activity, not just by clinical responses, but also even more so with symptom responses sooner. And overall, it was well tolerated as seen in the overall AGAVE 201 study.

Related Videos

Hematologic Malignancies
Supportive Care

Nikolaos Katsivelos, MD, and John Levine, MD, MS, on How Serial Clinical and Biomarker Monitoring During Treatment Can Stratify Patients With Low-Risk GVHD

Nikolaos Katsivelos, MD, and John Levine, MD, MS, of Icahn School of Medicine at Mount Sinai report on an investigation into the potential for serial monitoring of graft-versus-host disease (GVHD) symptom severity and MAGIC algorithm probabilities in patients with clinical and biomarker-defined low-risk GVHD to further risk-stratify patients into clinically meaningful groups (Abstract 380).

Lymphoma

Maayan Levy, PhD, and Marco Ruella, MD, on How a Ketogenic Diet Enhances CAR T-Cell Antitumor Function Via Beta-Hydroxybutyrate (BHB)

Maayan Levy, PhD, and Marco Ruella, MD, of the University of Pennsylvania, Perelman School of Medicine, discuss findings on whether ketogenic diet-derived BHB can be provided as a dietary intervention to augment CAR-T function in multiple cancer models. The results of this study will be translated into a first-in-human clinical trial of BHB-supplementation during CAR-T 19 treatment for relapsed or refractory B cell lymphoma. The data were presented during the ASH Plenary Scientific Session (Abstract 4). 

Hematologic Malignancies

Jenny Paredes, PhD, on How Increased Fiber Intake Results in Better Overall Survival and Lower GI-aGVHD in Allo-HCT Recipients and Pre-Clinical GVHD Models

Jenny Paredes, PhD, of City of Hope National Medical Center, discusses a study investigating the effects of dietary fiber on acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation (allo-HCT). The researchers evaluated a preclinical mouse model of GVHD with defined diet fiber concentrations and analyzed the dietary patterns of 173 allo-HCT patients (Abstract 259).

Leukemia

Rachel E. Rau, MD, and Sumit Gupta, MD, PhD, on Pediatric B-Cell ALL: Blinatumomab Added to Chemotherapy in Newly Diagnosed Disease

Rachel E. Rau, MD, of Seattle Children’s Hospital, and Sumit Gupta, MD, PhD, of the Hospital for Sick Children in Toronto, review results from Children’s Oncology Group Study AALL1731, which assessed the addition of blinatumomab to chemotherapy in newly diagnosed childhood standard-risk B-cell acute lymphoblastic leukemia (ALL). She explains how the combination may be considered a major breakthrough and new treatment standard in this patient population (Abstract 1).

Hematologic Malignancies

John O. Mascarenhas, MD, on Relapsed/Refractory Myelofibrosis: Navtemadlin vs Best Available Therapy After JAK Inhibitor Treatment

John O. Mascarenhas, MD, of Icahn School of Medicine at Mount Sinai, discusses the results of the phase III BOREAS study evaluating the efficacy and safety of single-agent navtemadlin vs best available therapy in patients with relapsed/refractory myelofibrosis who had previously received JAK inhibitor therapy. Navtemadlin is a potent, selective, orally available MDM2 inhibitor that restores p53 function (Abstract 1000).  

Advertisement

Advertisement




Advertisement